MoonLake Immunotherapeutics Gets Bullish Upgrade: Analyst Sees $40 Target as FDA Path Clears for Sonelokimab in HS

Rothschild Redburn upgrades MoonLake to Buy from Neutral. Sonelokimab's FDA path for HS clears major hurdle; seen as best-in-class contender attractive to big pharma.